Becton, Dickinson and Company
https://www.bd.com/en-us
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Becton, Dickinson and Company
Servier: Precision Approach To Immunotherapy Will Define New Oncology Era
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
Zest Is Back At Zealand With Cash Injection And A Clinical Win
The Danish biotech is looking to end 2022 on a high after raising over $105m and posting positive Phase III data on glepaglutide.
AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- BD
- BD Medical
- Bridger Biomed, Inc.
- Caesarea Medical Electronics
- CareFusion
- Carmel Pharma, Inc.
- Carmel Pharma, AB
- Cellular Research, Inc.
- C.R. Bard, Inc.
- CRISI Medical Systems
- Davol, Inc.
- Embo Medical Limited
- FlowCardia, Inc.
- GenCell Biosystems, Ltd.
- GeneOhm Sciences
- Liberator Medical, Inc.
- Lutonix, Inc.
- Medafor, Inc.
- Medicon, Inc.
- Neomend, Inc.
- Sirigen Group Limited
- TriPath Imaging
- TVA Medical, Inc.
- Rochester Medical, Inc.
- Safety Syringes Inc.
- Vascular Pathways, Inc.
- Venclose, Inc.